Skip to content

We have expanded our COVID-19 treatment phase 2 clinical trial footprint within the EU.-

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS/EVENTS
PUBLICATIONS
CONTACT

News/Events

Exciting news about plasma gelsolin therapy and BioAegis Therapeutics discoveries on infectious, inflammatory and degenerative diseases.

News

March, 2019: BioAegis Therapeutics Awarded European Patent Protection for the Uses of Plasma Gelsolin to Treat Infections

February 2019: BioAegis Therapeutics Expands Phase 1b/2a Community- Acquired Pneumonia Study to the Republic of Georgia — Successfully Completes Second of Four Dosing Cohorts

February 2019: BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study

December, 2018: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Five Granted Patents in 2018

September, 2018: BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round

June, 2018: BioAegis Therapeutics Abstract Presented at ASM-Microbe

December, 2017: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2017

November, 2017: Community Acquired Pneumonia Etiology Review in Clinical Infectious Diseases Reinforces Need for Host-Based Approach

October, 2017: BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

October, 2017: BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

Page1 Page2 Page3 Page4 Page5 … Page7

Events

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

Tweets by BioAegis

Stay informed of our latest discoveries and news.

EMAIL

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

FOLLOW US

JOIN OUR TEAM

©2020 BioAegis® Therapeutics Inc. | Privacy Policy | Terms of Use